logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12544379 B1

PDFFull Text
Date of Patent:
Feb. 10, 2026

Filed:

Sep. 19, 2023

Combination therapy using ribociclib and fulvestrant for the treatment of hr+ breast cancer

Applicant:

Novartis Ag, Basel, CH;

Inventors:

Yan Chen, Lexington, MA (US);

Xizhong Huang, Southborough, MA (US);

Sunkyu Kim, Arlington, MA (US);

Assignee:

Novartis AG, Basel, CH;

Attorney:

Michael Gottselig

Primary Examiner:

Kortney L Klinkel

Assistant Examiner:

Alison Azar Salamatian

Int. Cl.
CPC ...
A61K 31/4196 (2006.01); A61K 31/138 (2006.01); A61K 31/427 (2006.01); A61K 31/436 (2006.01); A61K 31/4439 (2006.01); A61K 31/495 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/551 (2006.01); A61K 31/5513 (2006.01); A61K 31/56 (2006.01); A61K 31/565 (2006.01); A61K 31/5685 (2006.01); A61K 45/06 (2006.01); A61P 5/00 (2006.01); A61P 5/32 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 43/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 31/138 (2013.01); A61K 31/436 (2013.01); A61K 31/4439 (2013.01); A61K 31/5377 (2013.01); A61K 31/551 (2013.01); A61K 31/5513 (2013.01); A61K 31/565 (2013.01); A61K 31/5685 (2013.01); A61K 45/06 (2013.01);
Abstract

The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.

Find Patent Forward Citations

Chen, Yan. (2026). Combination therapy using ribociclib and fulvestrant for the treatment of hr+ breast cancer (U.S. Patent No. 12544379). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12544379

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…